A PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY OF ALXN1210 VERSUS ECULIZUMAB IN COMPLEMENT INHIBITOR-NAIVE ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
- Registry ID
- ALXN1210-PNH-301
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- ALEXION PHARMACEUTICALS INC
- Start date
- 2016-12-13
- Last update
- 2016-11-03
Conditions
- PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
Related clinical trials
- A SINGLE ARM STUDY TO EVALUATE THE EFFICACY AND SAFETY OF POZELIMAB
AND CEMDISIRAN COMBINATION THERAPY IN PATIENTS WITH PAROXYSMAL
NOCTURNAL HEMOGLOBINURIA WITH INADEQUATE CONTROL OF INTRAVASCULAR
HEMOLYSIS ON CURRENTLY AVAILABLE C5 INHIBITOR THERAPY
- A PHASE 3 OPEN-LABEL STUDY OF DANICOPAN AS ADD-ON TREATMENT TO RAVULIZUMAB
OR ECULIZUMAB IN PEDIATRIC PARTICIPANTS WITH PAROXYSMAL NOCTURNAL
HEMOGLOBINURIA WHO HAVE CLINICALLY SIGNIFICANT EXTRAVASCULAR HEMOLYSIS
- A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY,
PHARMACOKINETICS, AND PRELIMINARY EFFICACY OF ALN-CFB, AN INVESTIGATIONAL SIRNA THERAPEUTIC AGAINST
COMPLEMENT FACTOR B, IN PARTICIPANTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA AND PERSISTENT ANEMIA ON
APPROVED C5-INHIBITOR THERAPY
- LONG-TERM EXTENSION (LTE) STUDY TO CHARACTERIZE THE SAFETY AND EFFICACY OF DANICOPAN AS AN ADD-ON THERAPY TO A COMPLEMENT COMPONENT 5 INHIBITOR (C5I) IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) PREVIOUSLY TREATED WITH DANICOPAN IN AN ALEXION-SPONSORED CLINICAL STUDY
- AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF POZELIMAB AND CEMDISIRAN COMBINATION THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
- A RANDOMIZED, OPEN-LABEL, RAVULIZUMAB-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF POZELIMAB AND CEMDISIRAN COMBINATION THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO ARE COMPLEMENT INHIBITOR TREATMENT-NAIVE OR HAVE NOT RECENTLY RECEIVED COMPLEMENT INHIBITOR THERAPY
View on source registry